



Search PubMed

for Sarkar and 2004 and Blood and 103

Go Clear

Advanced Search
Save Search

1: Blood. 2004 Feb 15;103(4):1253-60. Epub 2003 Oct 9.

Display AbstractPlus Show 20 Sort By Send to

1: Blood. 2004 Feb 15;103(4):1253-60. Epub 2003 Oct 9.

Total correction of hemophilia A mice with canine FVIII using an AAV 8 serotype.**Sarkar R, Tetreault R, Gao G, Wang L, Bell P, Chandler R, Wilson JM, Kazazian HH Jr.**

Department of Genetics, University of Pennsylvania 415 Curie Blvd, CRB Rm 475, Philadelphia, PA 19104, USA. sarkar@mail.med.upenn.edu

Despite the popularity of adeno-associated virus 2 (AAV2) as a vehicle for gene transfer, its efficacy for liver-directed gene therapy in hemophilia A or B has been suboptimal. Here we evaluated AAV serotypes 2, 5, 7, and 8 in gene therapy of factor VIII (FVIII) deficiency in a hemophilia A mouse model and found that AAV8 was superior to the other 3 serotypes. We expressed canine 8 domain-deleted FVIII cDNA either in a single vector or in 2 separate AAV vectors containing the heavy- and light-chain cDNAs. We also evaluated AAV8 against AAV2 in intraportal and tail vein injections. AAV8 gave 100% correction of plasma FVIII activity irrespective of the vector type or route of administration.

PMID: 14551134 [PubMed - indexed for MEDLINE]

Related articles

Multyear therapeutic benefit of AAV serotypes 2, 8, and 8 delivering factor VIII to hemophilia A mice and dogs.

Phenotypic correction of a mouse model of hemophilia A using AAV2 vectors encoding the heavy and light chain.

Long-term efficacy of adeno-associated virus serotypes 8 and 9 in hemophilia a dogs and mice

Gene therapy for the hemophilias

Preclinical gene therapy studies for hemophilia using adeno-associated virus (AAV) vectors.

x See reviews... | x See all.

Cited by PubMed Central articles

Application of a haematopoietic progenitor cell-targeted adeno-associated viral (AAV) vector established by

Complete correction of hemophilia A with adeno-associated viral vectors containing a full-length expression

Gene therapy for haemophilia

x See all (17)

Patient Drug Information

Anti-hemophilic Factor (Recombinant) (Helixate® FS, Kogenate® FS, Recombinate®...) Your doctor has ordered anti-hemophilic factor (recombinant) to help you

Recent Activity

Turn Off Clear

Total correction of hemophilia A mice with canine FVIII using an AAV 8 serotype

Sarkar and 2004 and Blood .. (1)

Sarkar and 2004 and Blood (150)

Sarkar and 2004 (1086)

Anti-Tac(Fv)-PE40, a single chain antibody Pseudomonas fusion protein directed at interferon ..

Display AbstractPlus Show 20 Sort By Send to

Write to the Help Desk

NLM | NIH

Department of Health & Human Services

Privacy Statement | Freedom of Information Act | Disclaimer

[\[Sign in\]](#) [\[Register\]](#)

Search PubMed

for

Go

Clear

Advanced Search

Display

AbstractPlus

Show 20

Sort By

Send to

1: Blood. 2004 Jan 1;103(1):85-92. Epub 2003 Sep 11.

Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1.

Arruda VR, Schuettrumpf J, Herzog RW, Nichols TC, Robinson N, Lotfi Y, Mingozzi F, Xiao W, Couto LB, High KA.

Department of Pediatrics, University of Pennsylvania Medical Center, The Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.

Adeno-associated viral (AAV) vectors (serotype 2) efficiently transduce skeletal muscle, and have been used as gene delivery vehicles for hemophilia B and for muscular dystrophies in experimental animals and humans. Recent reports suggest that AAV vectors based on serotypes 1, 5, and 7 transduce murine skeletal muscle much more efficiently than AAV-2, with reported increases in expression ranging from 2-fold to 1000-fold. We sought to determine whether this increased efficacy could be observed in species other than mice. In immunodeficient mice we saw 10- to 20-fold higher levels of human factor IX (hF.IX) expression at a range of doses, and in hemophilic dogs we observed approximately 50-fold higher levels of expression. The increase in transgene expression was due partly to higher gene copy number and a larger number of cells transduced at each injection site. In all immunocompetent animals injected with AAV-1, inhibitory antibodies to F.IX developed, but in immunocompetent mice treated with high doses of vector, inhibitory antibodies eventually disappeared. These studies emphasize that the increased efficacy of AAV-1 vectors carries a risk of inhibitor formation, and that further studies will be required to define doses and treatment regimens that result in tolerance rather than immunity to F.IX.

PMID: 12969984 [PubMed - indexed for MEDLINE]

Related articles

Theodore E. Woodward Award, AAV-mediated gene transfer for hemophilia.

AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B.

Efficient induction of immune tolerance to coagulation factor IX following direct intramuscular gene transfer

Therapeutic levels of factor IX expression using a muscle-specific promoter and adeno-associated virus

AAV-mediated gene transfer for hemophilia

» See reviews ... » See all...

Cited by PubMed Central articles

Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX

Viral-mediated gene therapy for the muscular dystrophies: successes, limitations and recent

Systemic protein delivery by muscle gene transfer is limited by a local immune response

» See all (4)

Recent Activity

Turn Off Clear

Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hem...

Arruda and 2004 and Blood... (2)

Arruda and 2004 and Blood (49)

Total correction of hemophilia A mice with canine FVIII using an AAV 8 serotype

Sarkar and 2004 and Blood... (1)

Display

AbstractPlus

Show 20

Sort By

Send to

Write to the Help Desk

NCBI | NLM | NIH

Department of Health & Human Services

Privacy Statement | Freedom of Information Act | Disclaimer



Search PubMed

for

Go Clear Advanced Search

[PubMed](#) [PubMed Central](#) [PubMed Bookshelf](#) [PubMed Researcher](#)

Display AbstractPlus Show 20 Sort By Send to

All Results

1: Hum Gene Ther. 2006 Aug;17(8):807-20.

Enhanced gene transfer efficiency in the murine striatum and an orthotopic glioblastoma tumor model, using AAV-7- and AAV-8-pseudotyped vectors.

Harding TC, Dickinson PJ, Roberts BN, Yendluri S, Gonzalez-Edick M, Lecouteur RA, Jooss KU.

Cell Genesys, South San Francisco, CA 94080, USA. thomash@cellgenesys.com

In this study, recombinant AAV vectors pseudotyped with viral capsids derived from AAV serotypes 7 and 8 were evaluated for gene transfer in the murine striatum relative to vectors pseudotyped with AAV serotypes 2, 5, and 6. In comparison with rAAV serotype 2, pseudotyped vectors derived from AAV-7 and AAV-8 have increased transduction efficiency in the murine CNS, with the rank order rAAV-7 > rAAV-8 > rAAV-5 > rAAV-2 = rAAV-6, with all vectors demonstrating a marked tropism for neuronal transduction. Pseudotyped rAAV vector gene transfer in the brain after preimplantation of a murine 4CB glioblastoma tumor was also evaluated. Efficiency of gene transfer to the orthotopic tumor was increased when using AAV-6, -7, and -8 capsid proteins in comparison with serotype 2, with the order rAAV-8 = rAAV-7 > rAAV-6 > rAAV-2 > rAAV-5. The increased gene transfer efficiency of rAAV vectors pseudotyped with the rAAV-8 capsid also provided enhanced therapeutic efficacy in a mouse model of glioblastoma multiforme, using vectors encoding an inhibitor of the vascular endothelial growth factor pathway. These studies demonstrate that rAAV vectors pseudotyped with capsids derived from AAV serotypes 7 and 8 provide enhanced gene transfer in the murine CNS and may offer increased therapeutic efficacy in the treatment of neurological disease.

PMID: 16942441 [PubMed - Indexed for MEDLINE]

Related articles

AAV serotype 8-mediated gene delivery of a soluble VEGF receptor to the CNS for the treatment of Rapamycin-regulated control of antiangiogenic tumor therapy following rAAV-mediated gene transfer. Adeno-associated virus (AAV) serotypes 2, 4 and 5 display similar transduction profiles and gene expression. The role of the adeno-associated virus capsid in gene transfer.

Custom adeno-associated virus capsids: the next generation of recombinant vectors with novel

» See reviews... » See all

Cited by PubMed Central articles

Tropism and toxicity of adeno-associated viral serotypes 1, 2, 5, 6, 7, 8, and 9 in rat neurons and glia

Recent Activity

Turn Off Clear

Enhanced gene transfer efficiency in the murine striatum and an orthotopic glioblastoma tu...

Harding and 2006 and Gene. (17)

Harding and 2006 and Gene (232)

Harding and 2006 (2060)

Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hem...

Display AbstractPlus Show 20 Sort By Send to

Write to the Help Desk

NCBI | NLM | NIH

Department of Health & Human Services

Privacy Statement | Freedom of Information Act | Disclaimer

Search PubMed

for Denby and 2005 and Gene therapy

Go

Clear

Advanced Search
Save Search

Display AbstractPlus Show 20 Sort By Send to

Display AbstractPlus


Show 20

Sort By

Send to

All 1 Results

1: Gene Ther. 2005 Oct;12(20):1534-8.

**Adeno-associated virus (AAV)-7 and -8 poorly transduce vascular endothelial cells and are sensitive to proteasomal degradation.****Denby L, Nicklin SA, Baker AH.**

British Heart Foundation, Glasgow Cardiovascular Research Centre, Division of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.

Transduction of the vascular endothelium by adeno-associated virus (AAV) vectors would have broad appeal for gene therapy. However, levels of transduction by AAV serotype-2 are low, an observation linked to deficiencies in endothelial cell binding, sequestration of virions in the extracellular matrix and/or virion degradation by the proteasome. Strategies to improve transduction of endothelial cells include AAV-2 capsid targeting using small peptides isolated by phage display or the use of alternate serotypes. Previously, we have shown that AAV serotypes-3 through -6 transduce endothelial cells with poor efficiency. Recently, AAV serotypes-7 and -8 have been shown to mediate efficient transduction of the skeletal muscle and liver, respectively, although their infectivity profile for vascular cells has not been addressed. Here, we show that AAV-7 and -8 also transduce endothelial cells with poor efficiency and the levels of transgene expression are markedly enhanced by inhibition of the proteasome. In both cases proteasome blockade enhances the nuclear translocation of virions. We further show that this is vascular cell-type selective since transduction of smooth muscle cells is not sensitive to proteasome inhibition. Analysis in intact blood vessels corroborated these findings and suggests that proteasome degradation is a common limiting factor for endothelial cell transduction by AAV vectors.

PMID: 15944728 [PubMed - indexed for MEDLINE]

Related articles

Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV

Development of efficient viral vectors selective for vascular smooth muscle cells

Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells

Receptor targeting of adeno-associated virus vectors

Progress in the use of adeno-associated viral vectors for gene therapy

» See reviews... | » See all...

Cited by PubMed Central articles

Recombinant adeno-associated virus transduction and integration

Cardiovascular gene therapy: current status and therapeutic potential

New vectors and strategies for cardiovascular gene therapy

Recent Activity

Turn Off Clear

Adeno-associated virus (AAV)-7 and -8 poorly transduce vascular endothelial cells and are ...

Denby and 2005 and Gene L... (1)

Enhanced gene transfer efficiency in the murine striatum and an orthotopic glioblastoma tu...

Harding and 2006 and Gene... (17)

Harding and 2006 and Gene (232)

Display AbstractPlus

Show 20

Sort By

Send to

Write to the Help Desk

NCBI | NLM | NIH

Department of Health & Human Services

Privacy Statement | Freedom of Information Act | Disclaimer



Search PubMed

for

Go Clear Advanced Search

Display AbstractPlus

Show 20

Sort By

Send to

All 1 results

1: J Virol. 2001 Feb;75(4):1824-33.

Final Version FREE

J Virol

Intracellular trafficking of adeno-associated virus vectors: routing to the late endosomal compartment and proteasome degradation.

Douar AM, Poulard K, Stockholm D, Danos O.

Genethon III-CNRS URA 1923, Evry, France. douar@genethon.fr

The early steps of adeno-associated virus (AAV) infection involve attachment to a variety of cell surface receptors (heparan sulfate, integrins, and fibroblast growth factor receptor 1) followed by clathrin-dependent or independent internalization. Here we have studied the subsequent intracellular trafficking of AAV particles from the endosomal compartment to the nucleus. Human cell lines were transduced with a recombinant AAV (rAAV) carrying a reporter gene (luciferase or green fluorescent protein) in the presence of agents that affect trafficking. The effects of bafilomycin A(1), brefeldin A, and MG-132 were measured. These drugs act at the level of endosome acidification, early-to-late endosome transition, and proteasome activity, respectively. We observed that the transducing virions needed to be routed as far as the late endosomal compartment. This behavior was markedly different from that observed with adenovirus particles. Antiproteasome treatments with MG-132 led to a 50-fold enhancement in transduction efficiency. This effect was accompanied by a 10-fold intracellular accumulation of single-stranded DNA AAV genomes, suggesting that the mechanism of transduction enhancement was different from the one mediated by a helper adenovirus, which facilitates the conversion of the rAAV single-stranded DNA genome into its replicative form. MG-132, a drug currently in clinical use, could be of practical use for potentializing rAAV-mediated delivery of therapeutic genes.

PMID: 11160681 [PubMed - indexed for MEDLINE]

Related articles

Ubiquitination of both adeno-associated virus type 2 and 5 capsid proteins affects the transduction efficiency of rAAV2 traffics through both the late and the recycling endosomes in a dose-dependent fashion.

Adeno-associated virus type 2-mediated gene transfer: altered endocytic processing enhances transduction

Intracellular trafficking of adeno-associated viral vectors.

Intracellular trafficking of adenovirus: many means to many ends.

» See reviews... | » See all

Cited by PubMed Central articles

A comparison of synthetic oligodeoxynucleotides, DNA fragments and AAV-1 for targeted epigenetic

Adeno-associated virus vector genomes persist as episomal chromatin in primate muscle

Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high efficiency

» See all (33)

Recent Activity

Turn Off Clear

Intracellular trafficking of adeno-associated virus vectors, routing to the late endosomal

Douar and 2001 (3)

Adeno-associated virus (AAV)-7 and -8 poorly transduce vascular endothelial cells and are

Denby and 2005 and Gene L... (1)

Enhanced gene transfer efficiency in the murine striatum and an orthotopic glioblastoma to

Display AbstractPlus

Show 20

Sort By

Send to

Write to the Help Desk

NCBI | NLM | NIH

Department of Health & Human Services

Privacy Statement | Freedom of Information Act | Disclaimer



Search PubMed

for

Go

Clear

Advanced Search

Display


AbstractPlus

Show 20

Sort By

Send to

1: Mol Ther. 2005 Apr;11(4):600-7.



Proteasome inhibition enhances AAV-mediated transgene expression in human synoviocytes in vitro and in vivo.

Jennings K, Miyamae T, Traister R, Marinov A, Katakura S, Sowders D, Trapnell B, Wilson JM, Gao G, Hirsch R.

William S. Rowe Division of Rheumatology, Children's Hospital Medical Center, Cincinnati, OH 45229, USA.

To explore the potential applicability of recombinant adeno-associated virus (rAAV) vectors in the treatment of rheumatoid arthritis (RA), primary human fibroblast-like synoviocytes (FLS) derived from patients with RA were infected with rAAV encoding mouse IL-10 under the control of the CMV promoter. Addition of the proteasome inhibitor carbobenzoxy-L-leucyl-L-leucyl-L-leucinal (zLLL) to the cultures dramatically enhanced expression of the IL-10 transgene, in a dose-dependent manner. The increased expression was transient, peaking at 3 days and returning to near baseline by 7 days. The enhancement was observed even when zLLL was added 13 days after infection with rAAV. The effect of zLLL was not specific to either the rAAV-10 transgene or the CMV promoter, as similar findings were observed using an rAAV construct encoding alpha1-anti-trypsin under the control of the chick beta-actin promoter or GFP, driven by the CMV promoter. Transgene expression could be repeatedly induced by reexposure to zLLL. Transgene mRNA levels increased in parallel with protein levels. Transgene expression could also be repeatedly induced in vivo by administering zLLL to SCID mice previously injected with rAAV-infected FLS. These data demonstrate that proteasome inhibition can dramatically enhance transgene expression in human RA FLS following infection with rAAV and suggest a possible approach to regulating synovial transgene expression in vivo.

PMID: 15771962 [PubMed - indexed for MEDLINE]

Related articles

Inflammatory cytokine regulation of transgene expression in human fibroblast-like synoviocytes: Empirical advantages of adeno-associated viral vectors in vivo gene therapy for arthritis

Recombinant adeno-associated virus type 2-mediated gene transfer into human keratinocytes is independent of

Inflammation-responsive promoters for fine-tuned gene therapy in rheumatoid arthritis

Promoters and regulatory elements that improve adeno-associated virus transgene expression

» See reviews... » See all...

Cited by PubMed Central articles

Gene therapy for arthritis.

Adeno-associated virus type 2 capsids with externalized VP1/VP2 trafficking domains are generated prior to CD147 overexpression on synoviocytes in rheumatoid arthritis enhances matrix metalloproteinase-2 production

Recent Activity

Turn Off Clear

Proteasome inhibition enhances AAV-mediated transgene expression in human synoviocytes

jennings and 2005 and the... (15)

jennings and 2005 and the... (210)

Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases

jennings and 2005 and mol (1)

Display

AbstractPlus

Show 20

Sort By

Send to

Write to the Help Desk

NCBI | NLM | NIH

Department of Health & Human Services

Privacy Statement | Freedom of Information Act | Disclaimer

NCBI
National Center for Biotechnology Information

Sign In | Register

Search PubMed

for

Go

Clear

Advanced Search

Display AbstractPlus

Show 20

Sort By

Send to

Alerts

1: Antimicrob Agents Chemother. 2004 Jul;48(7):2437-47.

Final Version FREE
aacc.asm.org

Related articles

An *Escherichia coli* expression assay and screen for human immunodeficiency virus protease variants with
Toward the development of a virus-cell-based assay for
the discovery of novel compounds against human

A quick diversity-oriented amide-forming reaction to
optimize P-subsite residues of HIV protease inhibitors

Design of HIV protease inhibitors targeting
protein backbone: an effective strategy for combating

Resilience to resistance of HIV-1 protease
inhibitors: profile of darunavir.

» See reviews... | » See all...

Cited by PubMed Central articles

Identification and biochemical characterization of small-
molecule inhibitors of wound-healing virus protease by

Patient Drug Information

Ampranavir (Agenerase®) | Ampranavir is used in
combination with other antiretroviral medications to treat
human immunodeficiency virus (HIV). Ampranavir

Recent Activity

Turn Off | Clear

Model system for high-throughput screening of
novel human immunodeficiency virus

cheng and 2004 and 48 and... (12)

cheng and 2004 and 48 (301)

cheng and 2004 vol 48 (0)

cheng and 2004 chemother (0)

Display AbstractPlus

Show 20

Sort By

Send to

Write to the Help Desk

NCBI | NLM | NIH

Department of Health & Human Services

Privacy Statement | Freedom of Information Act | Disclaimer

[\[Sign In\]](#) [\[Register\]](#)

Search PubMed

for

[Go](#) [Clear](#) [Advanced Search](#)

[Links](#) [Privacy Policy](#) [History](#) [Comments](#) [Help](#)

Display AbstractPlus Show 20 Sort By Send to

All 1 To 1 of 1

1: J Biol Chem. 2002 Oct 11;277(41):38322-7. Epub 2002 Aug 6.

Final Version **FREE**
Full Text

Identification and biological characterization of heterocyclic inhibitors of the hepatitis C virus RNA-dependent RNA polymerase.

Dhanak D, Duffy KJ, Johnston VK, Lin-Goerke J, Darcy M, Shaw AN, Gu B, Silverman C, Gates AT, Nonnemacher MR, Earnshaw DL, Casper DJ, Kaura A, Baker A, Greenwood C, Gutshall LL, Maley D, DeVecchio A, Macarron R, Hofmann GA, Alnoah Z, Cheng HY, Chan G, Khandekar S, Keenan RM, Sarisky RT.

Department of Medicinal Chemistry, The Musculoskeletal, Microbial and Proliferative Diseases Center of Excellence for Drug Discovery, GlaxoSmithKline Pharmaceuticals, Collegeville, Pennsylvania 19426, USA.

The hepatitis C virus (HCV) NS5B protein encodes an RNA-dependent RNA polymerase (RdRp), the primary catalytic enzyme of the HCV replicase complex. We established a biochemical RNA synthesis assay, using purified recombinant NS5B lacking the C-terminal 21 amino acid residues, to identify potential polymerase inhibitors from a high throughput screen of the GlaxoSmithKline proprietary compound collection. The benzo-1,2,4-thiadiazine compound 1 was found to be a potent, highly specific inhibitor of NS5B. This agent interacts directly with the viral polymerase and inhibits RNA synthesis in a manner noncompetitive with respect to GTP. Furthermore, in the absence of an in vitro-reconstituted HCV replicase assay employing viral and host proteins, the ability of compound 1 to inhibit NS5B-directed viral RNA replication was determined using the Huh7 cell-based HCV replicon system. Compound 1 reduced viral RNA in replicon cells with an IC(50) of approximately 0.5 microm, suggesting that the inhibitor was able to access the perinuclear membrane and inhibit the polymerase activity in the context of a replicase complex. Preliminary structure-activity studies on compound 1 led to the identification of a modified inhibitor, compound 4, showing an improvement in both biochemical and cell-based potency. Lastly, data are presented suggesting that these compounds interfere with the formation of negative and positive strand progeny RNA by a similar mode of action. Investigations are ongoing to assess the potential utility of such agents in the treatment of chronic HCV disease.

PMID: 12167642 [PubMed - indexed for MEDLINE]

Related articles

Resistance profile of a hepatitis C virus RNA-dependent RNA polymerase bioassay: a rabbit ...

Specific inhibitors of HCV polymerase identified using an NS5B with lower affinity for template primer

Arresting initiation of hepatitis C virus RNA synthesis using heterocyclic derivatives.

Nucleoside analog inhibitors of hepatitis C virus replication

Allosteric inhibition of the hepatitis C virus NS5B RNA dependent RNA polymerase

[» See reviews](#) [» See all](#)

Cited by PubMed Central articles

Consensus siRNA for inhibition of HCV genotype-4 replication.

Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase

Molecular mechanism of hepatitis C virus replicon variants with reduced susceptibility to a benzoxazinone

[» See all \(24\)](#)

Recent Activity

[Turn Off](#) [Clear](#)

Identification and biological characterization of heterocyclic inhibitors of the hepatitis ...

dhanak and 2002 (4)

Model system for high-throughput screening of novel human immunodeficiency virus

cheng and 2004 and 48 ant ... (12)

cheng and 2004 and 48 (301)

Display AbstractPlus Show 20 Sort By Send to

Write to the Help Desk

NCBI | NLM | NIH

Department of Health & Human Services

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)